Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.
With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.
Abera develops a pipeline of vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also explores applications in personalized immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Abera Bioscience (“Abera” or “the Company”) has concluded the last toxicological study with Ab-01.12 and received the final report, demonstrating that the vaccine is well-tolerated,
Abera Bioscience AB (“Abera” or “the Company”) is actively advancing its vaccine candidates, leveraging proprietary vaccine platforms centered around Outer Membrane Vesicles (OMVs) and Protein
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT TREDJE KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 0 (1 047) kSEK Resultatet efter finansiella
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.